Sionna Therapeutics, Inc.
SIONFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Sionna Therapeutics, Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 2 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 18, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Sionna Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-05-11 · Thompson Peter A.: Larger than 146 of the 152 other insider sales of Common Stock on file. SEC filing
- 2026-05-11 · ORBIMED ADVISORS LLC: Larger than 146 of the 152 other insider sales of Common Stock on file. SEC filing
- 2026-05-08 · ORBIMED ADVISORS LLC: Larger than 137 of the 152 other insider sales of Common Stock on file. SEC filing
- 2026-05-08 · Thompson Peter A.: Larger than 137 of the 152 other insider sales of Common Stock on file. SEC filing
- 2026-04-16 · ORBIMED ADVISORS LLC: Larger than 148 of the 152 other insider sales of Common Stock on file. SEC filing
- 2026-04-16 · Thompson Peter A.: Larger than 148 of the 152 other insider sales of Common Stock on file. SEC filing
- 2026-04-15 · Thompson Peter A.: Larger than 150 of the 152 other insider sales of Common Stock on file. SEC filing
- 2026-04-15 · ORBIMED ADVISORS LLC: Larger than 150 of the 152 other insider sales of Common Stock on file. SEC filing
- 2026-01-22 · COULTER JAMES G: Larger than all 152 other insider sales of Common Stock on file. SEC filing
- 2025-11-24 · ORBIMED ADVISORS LLC: Larger than 142 of the 152 other insider sales of Common Stock on file. SEC filing
- 2025-11-24 · Thompson Peter A.: Larger than 142 of the 152 other insider sales of Common Stock on file. SEC filing
- 2025-10-24 · RA Capital Healthcare Fund LP: Larger than 145 of the 152 other insider sales of Common Stock on file. SEC filing
- 2025-10-24 · RA Capital Healthcare Fund LP: Larger than 140 of the 152 other insider sales of Common Stock on file. SEC filing
- 2025-10-24 · RA Capital Healthcare Fund LP: Larger than 144 of the 152 other insider sales of Common Stock on file. SEC filing
- 2025-10-16 · Booth Bruce: Larger than 141 of the 152 other insider sales of Common Stock on file. SEC filing
- 2025-10-15 · Booth Bruce: Larger than 139 of the 152 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2025-02-10–2025-02-10: 7 event(s) across 6 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-27 | ORBIMED ADVISORS LLC · Director | Common Stock | S — Open market or private sale | −101 | 44.49 | SEC filing |
| 2026-05-27 | Thompson Peter A. · Director | Common Stock | S — Open market or private sale | −101 | 44.49 | SEC filing |
| 2026-05-11 | ORBIMED ADVISORS LLC · Director | Common Stock | S — Open market or private sale | −184,639 | 46.22 | SEC filing |
| 2026-05-11 | Thompson Peter A. · Director | Common Stock | S — Open market or private sale | −184,639 | 46.22 | SEC filing |
| 2026-05-08 | Thompson Peter A. · Director | Common Stock | S — Open market or private sale | −59,767 | 44.58 | SEC filing |
| 2026-05-08 | ORBIMED ADVISORS LLC · Director | Common Stock | S — Open market or private sale | −59,767 | 44.58 | SEC filing |
| 2026-05-07 | Thompson Peter A. · Director | Common Stock | S — Open market or private sale | −48,546 | 44.61 | SEC filing |
| 2026-05-07 | ORBIMED ADVISORS LLC · Director | Common Stock | S — Open market or private sale | −48,546 | 44.61 | SEC filing |
Showing 8 of 18 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-17 | Stelzer Laurie · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +17,340 | SEC filing |
| 2026-06-17 | Ruddy Marcella K. · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +17,340 | SEC filing |
| 2026-06-17 | Fleming Harold Edward · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +17,340 | SEC filing |
| 2026-06-17 | Resnick Joshua · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +17,340 | SEC filing |
| 2026-06-17 | Thompson Peter A. · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +17,340 | SEC filing |
| 2026-06-17 | Clancy Paul J · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +17,340 | SEC filing |
| 2026-06-17 | RA Capital Healthcare Fund LP · Director, 10% owner | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +17,340 | SEC filing |
| 2026-06-17 | Booth Bruce · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +17,340 | SEC filing |
Showing 8 of 20 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.